\n\u201cWe are very pleased with our strong pipeline progress during the quarter amid such challenging times,\u201d said Frank Lee, President and Chief Executive Officer of Forma. \u201cWe look forward to presenting new data from our ongoing Phase 1 trial of FT-4202 in sickle cell disease at the ASH meeting in December, as well as beginning enrollment of patients for our Phase 1 trial of FT-7051 in men living with metastatic castration-resistant prostate cancer. The recent positive top-line results from the olutasidenib registrational Phase 2 clinical trial in relapsed\/refractory acute myeloid leukemia with an IDH1 mutation further underscores our commitment to developing transformative therapies for patients.\u201d\n<\/p>\n
Key Business and Clinical Highlights<\/span><\/b><\/p>\n PKR Program in Sickle Cell Disease (SCD): <\/b><\/p>\n CPB\/p300 Program in Prostate Cancer: <\/b><\/p>\n IDH1 Program in AML and Glioma:<\/b><\/p>\n Corporate:<\/b><\/p>\n Upcoming Milestones<\/span><\/b><\/p>\n Upcoming Investor Events <\/b><\/p>\n Financial Results<\/span><\/b><\/p>\n About Forma Therapeutics<\/b><\/p>\n \nForma Therapeutics is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Our R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create drug candidates with differentiated mechanisms of action focused on indications with high unmet need. Our work has generated a broad proprietary portfolio of programs with the potential to provide profound patient benefit. For more information, please visit www.FormaTherapeutics.com<\/a> or follow us on Twitter @FORMAInc and LinkedIn.\n<\/p>\n Forward-looking Statements<\/b><\/p>\n \nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the company\u2019s beliefs and expectations regarding its: business plans and objectives; future plans for FT-4202 and FT-7051, including expectations regarding timing and success of the current ongoing clinical trials, therapeutic potential and clinical benefits thereof, and upcoming milestones for the company\u2019s other product candidates; growth as a company and the anticipated contribution of the members of our board of directors to our operations and progress; presentation of additional data at upcoming scientific conferences, and other preclinical data in 2020; the potential commercial and collaboration opportunities, including potential future collaborators and parties, as well as value and market, for our product candidates; uses of capital, expenses and other 2020 financial results or in the future, and the potential impact of COVID-19 on patient retention, strategy, future operations, clinical trials or IND submissions. The words \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201ctarget\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.\n<\/p>\n \nAny forward-looking statements in this press release are based on management\u2019s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties associated with: the impact of the COVID-19 pandemic on the company\u2019s business, operations, strategy, goals and anticipated milestones; the therapeutic potential of FT-4202, and the timing associated with the initiation or continuation of any of FT-4202 trials; the initiation of our phase I clinical trial of FT-7051; Forma\u2019s ability to execute on its strategy; positive results from a clinical study may not necessarily be predictive of the results of future or ongoing clinical studies; regulatory developments in the United States and foreign countries; Forma\u2019s ability to fund operations; Forma\u2019s ability to identify satisfactory collaboration opportunities, as well as those risks and uncertainties set forth more fully under the caption “Risk Factors” in the final prospectus dated June 22, 2020 and filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended, with the United States Securities and Exchange Commission (SEC) and elsewhere in Forma\u2019s filings and reports with the SEC. Forma disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent Forma\u2019s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Forma explicitly disclaims any obligation to update any forward-looking statements.\n<\/p>\n 2020<\/b><\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n 2019<\/b><\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n 2020<\/b><\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n 2019<\/b><\/p>\n<\/td>\n<\/tr>\n \n\u00a0$\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 –\u00a0\u00a0\n<\/p>\n<\/td>\n \n\u00a0$\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 3,377\n<\/p>\n<\/td>\n \n\u00a0$\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 –\u00a0\u00a0\n<\/p>\n<\/td>\n \n\u00a0$\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 93,113\n<\/p>\n<\/td>\n<\/tr>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 24,780\n<\/p>\n<\/td>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 27,558\n<\/p>\n<\/td>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 68,501\n<\/p>\n<\/td>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 84,273\n<\/p>\n<\/td>\n<\/tr>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 7,460\n<\/p>\n<\/td>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 7,025\n<\/p>\n<\/td>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 22,841\n<\/p>\n<\/td>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 17,631\n<\/p>\n<\/td>\n<\/tr>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 –\u00a0\u00a0\n<\/p>\n<\/td>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 545\n<\/p>\n<\/td>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 63\n<\/p>\n<\/td>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 5,620\n<\/p>\n<\/td>\n<\/tr>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 32,240\n<\/p>\n<\/td>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 35,128\n<\/p>\n<\/td>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 91,405\n<\/p>\n<\/td>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 107,524\n<\/p>\n<\/td>\n<\/tr>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (32,240)\n<\/p>\n<\/td>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (31,751)\n<\/p>\n<\/td>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (91,405)\n<\/p>\n<\/td>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (14,411)\n<\/p>\n<\/td>\n<\/tr>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 818\n<\/p>\n<\/td>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 766\n<\/p>\n<\/td>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 23,050\n<\/p>\n<\/td>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 3,057\n<\/p>\n<\/td>\n<\/tr>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (31,422)\n<\/p>\n<\/td>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (30,985)\n<\/p>\n<\/td>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (68,355)\n<\/p>\n<\/td>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (11,354)\n<\/p>\n<\/td>\n<\/tr>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (3,806)\n<\/p>\n<\/td>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 –\u00a0\u00a0\n<\/p>\n<\/td>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (26,529)\n<\/p>\n<\/td>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (1,217)\n<\/p>\n<\/td>\n<\/tr>\n \n\u00a0$\u00a0\u00a0\u00a0\u00a0 (27,616)\n<\/p>\n<\/td>\n \n\u00a0$\u00a0\u00a0\u00a0\u00a0 (30,985)\n<\/p>\n<\/td>\n \n\u00a0$\u00a0\u00a0\u00a0\u00a0 (41,826)\n<\/p>\n<\/td>\n \n\u00a0$\u00a0\u00a0\u00a0\u00a0 (10,137)\n<\/p>\n<\/td>\n<\/tr>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 –\u00a0\u00a0\n<\/p>\n<\/td>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (607)\n<\/p>\n<\/td>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (3,736)\n<\/p>\n<\/td>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (2,395)\n<\/p>\n<\/td>\n<\/tr>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 –\u00a0\u00a0\n<\/p>\n<\/td>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 –\u00a0\u00a0\n<\/p>\n<\/td>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 –\u00a0\u00a0\n<\/p>\n<\/td>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (11,347)\n<\/p>\n<\/td>\n<\/tr>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 –\u00a0\u00a0\n<\/p>\n<\/td>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (60)\n<\/p>\n<\/td>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 –\u00a0\u00a0\n<\/p>\n<\/td>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (60)\n<\/p>\n<\/td>\n<\/tr>\n \n\u00a0$\u00a0\u00a0\u00a0\u00a0 (27,616)\n<\/p>\n<\/td>\n \n\u00a0$\u00a0\u00a0\u00a0\u00a0 (45,562)\n<\/p>\n<\/td>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (8)\n<\/p>\n<\/td>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 –\u00a0\u00a0\n<\/p>\n<\/td>\n \n\u00a0$\u00a0\u00a0\u00a0\u00a0 (27,624)\n<\/p>\n<\/td>\n \n\u00a0$\u00a0\u00a0\u00a0\u00a0 (45,562)\n<\/p>\n<\/td>\n \n\u00a0$\u00a0\u00a0\u00a0\u00a0 (31,652)\n<\/p>\n<\/td>\n \n\u00a0$\u00a0\u00a0\u00a0\u00a0 (23,939)\n<\/p>\n<\/td>\n<\/tr>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (198)\n<\/p>\n<\/td>\n \n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (515)\n<\/p>\n<\/td>\n<\/tr>\n \n\u00a0$\u00a0\u00a0\u00a0\u00a0 (31,850)\n<\/p>\n<\/td>\n \n\u00a0$\u00a0\u00a0\u00a0\u00a0 (24,454)\n<\/p>\n<\/td>\n<\/tr>\n \n\u00a0$\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (0.67)\n<\/p>\n<\/td>\n \n\u00a0$\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (2.74)\n<\/p>\n<\/td>\n \n\u00a0$\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (0.67)\n<\/p>\n<\/td>\n \n\u00a0$\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (2.74)\n<\/p>\n<\/td>\n \n\u00a0$\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (12.42)\n<\/p>\n<\/td>\n \n\u00a0$\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (9.40)\n<\/p>\n<\/td>\n<\/tr>\n \n\u00a0$\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (12.50)\n<\/p>\n<\/td>\n \n\u00a0$\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (9.60)\n<\/p>\n<\/td>\n<\/tr>\n \n41,088,261\n<\/p>\n<\/td>\n \n16,616,143\n<\/p>\n<\/td>\n \n41,088,924\n<\/p>\n<\/td>\n \n16,616,143\n<\/p>\n<\/td>\n \n2,547,924\n<\/p>\n<\/td>\n \n2,547,924\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n\n
\n
\n
\n
\n
\n
\n
\n
\n \n Selected Financial Information<\/b><\/td>\n<\/tr>\n \n \n (in thousands except share and per share data)\u00a0<\/td>\n<\/tr>\n \n \n (unaudited)\u00a0<\/td>\n<\/tr>\n \n \n \n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n Statement of Operations Items:<\/td>\n \n Three Months Ended
September\u00a030,<\/b><\/td>\n\n Nine Months Ended
September\u00a030,<\/b><\/td>\n<\/tr>\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n Revenue<\/td>\n \n \n \n \n \n \n \n \n \n Operating expenses<\/td>\n \n \n \n \n \n \n \n <\/tr>\n \n \n Research and development<\/td>\n \n \n \n \n \n \n \n \n \n \n General and administrative<\/td>\n \n \n \n \n \n \n \n \n \n \n Restructuring charges<\/td>\n \n \n \n \n \n \n \n \n \n Total operating expenses<\/td>\n \n \n \n \n \n \n \n \n \n Loss from operations<\/td>\n \n \n \n \n \n \n \n \n \n Other income, net<\/td>\n \n \n \n \n \n \n \n \n \n Loss before taxes<\/td>\n \n \n \n \n \n \n \n \n \n Income tax benefit<\/td>\n \n \n \n \n \n \n \n \n \n Net loss<\/td>\n \n \n \n \n \n \n \n \n \n Preferred return and accretion of preferred return and
cumulative dividends on preferred securities<\/td>\n\n \n \n \n \n \n \n \n \n Distribution to holders of preferred securities in excess of
accrued preferred return<\/td>\n\n \n \n \n \n \n \n \n \n Tax distribution to holders of Enterprise.1 Incentive Shares<\/td>\n \n \n \n \n \n \n \n \n \n Net loss allocable to shares of common stock, basic\u00a0<\/td>\n \n \n \n \n \n \n \n <\/tr>\n \n Change in fair value attributable to warrants to purchase
common stock<\/td>\n\n \n \n \n \n \n \n <\/tr>\n \n Net loss allocable to shares of common stock, diluted<\/td>\n \n \n \n \n \n \n \n <\/tr>\n \n Net loss allocable to shares of Common 1, basic\u00a0<\/td>\n \n \n \n \n \n \n \n \n \n Change in fair value attributable to warrants to purchase
preferred securities<\/td>\n\n \n \n \n \n \n \n \n \n Net loss allocable to shares of Common 1, diluted<\/td>\n \n \n \n \n \n \n \n \n \n Net loss per share of common stock:<\/td>\n \n \n \n \n \n \n \n <\/tr>\n \n \n Basic<\/td>\n \n \n \n \n \n \n \n <\/tr>\n \n \n Diluted<\/td>\n \n \n \n \n \n \n \n <\/tr>\n \n Net loss per share of Common 1:<\/td>\n \n \n \n \n \n \n \n <\/tr>\n \n \n Basic<\/td>\n \n \n \n \n \n \n \n \n \n \n Diluted<\/td>\n \n \n \n \n \n \n \n \n \n Weighted-average shares of common stock outstanding:<\/td>\n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n \n Basic<\/td>\n \n \n \n \n \n \n \n <\/tr>\n \n \n Diluted<\/td>\n \n \n \n \n \n \n \n <\/tr>\n \n Weighted-average shares of Common 1 outstanding, basic
and diluted<\/td>\n\n \n \n \n \n \n \n \n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20201112005167\/en\/786095\/3\/logo_-_new_4.7.2020.jpg\"){kind=logo}
<\/td>\n<\/tr>\n